Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigadexa for post-cataract surgery inflammation/infection
NCT00870103Phase 4
Key facts
- Status
- Completed
- Start
- Sep 2008
- Primary completion
- Feb 2009
- Countries
- 1
- Sponsor
- Alcon Inc.
- Modality
- Orthosteric Ligands
- Conditions
- post-operative inflammationpost-operative infection
01
Overview
Phase 4, open-label, single-arm trial of Moxisurge and dexamethasone in post-operative inflammation and post-operative infection, sponsored by Alcon Inc. Primary endpoints: Percentage of Patients With a Score of Zero for Anterior Chamber Cells at Day 15 and Percentage of Patients With no Ocular Pain at Day 15. Started Sep 2008; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Vigadexa eye drops
Moxifloxacin 0.5% and dexamethasone 0.1% eye drops
03
Who it enrols
Adult patients undergoing cataract extraction with IOL implantation, excluding those with uncontrolled glaucoma or recent use of ocular anti-infectives or steroids.
04
Endpoints
Primary
Percentage of Patients With a Score of Zero for Anterior Chamber Cells
Percentage of Patients With no Ocular Pain
Beyond the preview
Go deeper on NCT00870103.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00870103.